Tomer Stavitsky is Senior Vice President and Chief Corporate Development Officer at Omnicell (NASDAQ: OMCL), where he leads corporate development and M&A strategy. He brings 15+ years of experience across healthcare, MedTech, digital health, AI, strategy, partnerships, and international M&A, with prior roles at Johnson & Johnson, Pfizer, Intuitive Surgical, ConvaTec, Ginkgo Bioworks, and Allurion. He has appeared on M&A Science to discuss M&A governance, deal teams, steering committees, and leading a deal from diligence through integration.
Tomer Stavitsky, SVP Corp Dev at Omnicell, explains how partnerships can strengthen pre-acquisition strategy, covering PE dynamics, ROFR structures, and milestone design.
Kison speaks with Tomer Stavitsky, former Corporate Development, Partnerships, and M&A Lead at Intuitive about building a steering committee that doesn't slow down the deal and what the M&A process looks like.